Fujita Health University Hospital

Toyoake, Aichi-ken 4701192

3 studies enrolling now · 13 studies all time

What they study most

ALK-positive Advanced NSCLC, Acute Non-cardioembolic Ischemic Stroke, COVID-19 Infection, FSGS, Grade 2 Glioma, Hepatocellular Carcinoma (HCC), High-risk Transient Ischemic Attack, Infectious Disease, Multiple System Atrophy, Multiple System Atrophy (MSA), NASH, Polycystic Kidney Disease, Autosomal Dominant

Studies at this site

• A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised — Recruiting now
• An International Observational Study of Adults With Acute Infection — Recruiting now
• A Retrospective Study to Characterize Participants With Propionic Acidemia — Recruiting now
• A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB — Recruiting now
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Running, not enrolling
• A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis — Completed
• A Study of Lu AF82422 in Participants With Multiple System Atrophy — Running, not enrolling
• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling
• Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) — Completed